Recently Introduced Products

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Potential Impact</th>
<th>Expected Avg. Cost per treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Durezol 0.05%</td>
<td>For the treatment of:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Inflammation and pain associated with post-operative inflammation following cataract surgery</td>
<td>$</td>
<td>$54</td>
</tr>
<tr>
<td></td>
<td>- Endogenous anterior uveitis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

$: Est. drug plan expenditure increase of <1%* $$: Est. drug plan expenditure increase of 1-5%* $$$$: Est. drug plan expenditure increase of >5%*

**Anoro Ellipta® – New Combination Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)**

Chronic obstructive pulmonary disease (COPD) is a progressive condition characterized by poor airflow and inflammation of the airways – often associated with smoking. As a result of lung tissue breakdown and small airway dysfunction, individuals with COPD often present with shortness of breath, cough as well as excess sputum production. These symptoms will progress with time and will significantly limit the physical functions and impair the quality of life of those affected.

COPD represents a major burden on healthcare resources in Canada. Not only is it the fourth leading cause of death and is the only chronic condition with increasing mortality, its prevalence in Canada is also on the rise with an estimated one in four people diagnosed with COPD in their lifetime. In particular, the working population is affected. Research has shown that COPD symptoms can significantly impact an individual’s productivity at work (i.e. reducing work hours and modifying work-related activities secondary to breathing problems). Therefore, it is of significant importance that we be able to effectively manage this disease in our world today.

The current standard of therapy for COPD symptom control includes one or a combination of the following bronchodilators (i.e. to open-up airway for better airflow): inhaled anticholinergics and inhaled beta2-agonists. Both come in short-acting and long-acting formulations but it is the latter that is mostly used for disease maintenance. Please note that the current treatment guideline suggests a step-wise approach to management – a 2nd long-acting bronchodilator is only added if symptoms persist with maximal doses of the 1st long-acting agent.

Anoro Ellipta® is a fixed dose combination medication of both a long-acting inhaled anticholinergic or muscarinic antagonist (LAMA) and a long-acting inhaled beta2-agonist (LABA); one of the few currently available in Canada. Head-to-head trials have confirmed that for those who primarily present with breathlessness and is at low risk for exacerbations, Anoro Ellipta®’s efficacy is superior to that of Spiriva monotherapy (LAMA), the current mainstay maintenance therapy for COPD. Other beneficial features of Anoro Ellipta® include: 1. convenience due of its one inhalation once daily dosing regimen and 2. a tolerable side effect profile.

Due to Anoro Ellipta®’s place in therapy, typically not 1st line treatment for COPD, and the premium cost associated with this medication (approx. $1,000 annually), it is recommended that Anoro Ellipta® be placed under Special Authorization for ClaimSecure groups that subscribe to the Managed Formulary. The Special Authorization process seeks to ensure that Anoro Ellipta® is used only for members with COPD and who have tried and failed on optimal doses of the 1st long-acting inhalation agent. For ClaimSecure groups subscribing to Specialty Drug, and Stop Loss Programs and Open Drug Formularies, Anoro Ellipta® will be fully covered.

*If you require additional information about Anoro Ellipta®, please contact the Clinical Services Department, at (905) 949-3025 or 1-888-479-7587 ext. 3025.*

**Recommendation: Special Authorization**

**ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines**

References:

* Based on the Financial Impact Analysis per 100,000 lives covered © 2014 ClaimSecure Inc.